Stopping blood thinners after antibodies disappear in thrombotic antiphospholipid syndrome
Compares stopping versus continuing blood thinners in thrombotic antiphospholipid syndrome after antibodies are gone.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 234 people, planned
- Starts
- Dec 2026
- Expected to end
- Jan 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vitamin K Antagonist - Drug
- Anticoagulant Therapy Discontinuation
- Record updated
- 15 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with thrombotic antiphospholipid syndrome (APS), a condition that causes blood clots. Their antiphospholipid antibodies must have gone back to normal while on long-term vitamin K antagonist blood thinners. The trial compares stopping the blood thinner with keeping it.
- Age
- 18 years and older.
- Sex
- All sexes.
- Disease stage
- Primary or secondary thrombotic APS according to the 2023 ACR/EULAR classification criteria.
- Earlier treatment
- Must have taken vitamin K antagonists (VKAs) for a long time (>12 months).
- Biomarker or test result
- LA, aCL and aβ2GPI antibodies must be at a normal level (< 99th percentile). This must show in at least two tests in a row, at least 12 months apart. One negative test must be within the 3 months before joining. People with triple aPL positivity cannot join.
Main reasons for not taking part
- Past arterial clot, severe venous clot, or a new venous clot while taking VKAs
- Past catastrophic antiphospholipid syndrome (CAPS)
- Mechanical heart valve or another condition that needs VKA blood thinners
- Active cancer, malignant hypertension or severe liver problems
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Adults ≥ 18 years old
- Signed written consent form
- Primary or secondary thrombotic APS according to 2023 ACR/EULAR classification criteria
- aPL antibodies loss of LA, aCL, and aβ2GPI antibodies - defined as a normalised level (< 99th percentile) - in at least two consecutive measurements with at least 12 months between each measurement including one negative measurement within the 3 months preceding inclusion
- Long term (>12 months) VKAs therapy
Who cannot take part
- History of recurrent venous thrombosis while receiving VKAs
- History of severe venous thrombosis. Severe venous thrombosis including massive pulmonary embolism; chronic thromboembolic pulmonary hypertension; hepatic, mesenteric, renal and/or cerebral venous thrombosis
- History of arterial thrombosis
- History of catastrophic antiphospholipid syndrome (CAPS)
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 for each VKAs medicinal product
- Malignant hypertension
- Severe hepatic impairment
- Active malignancy
- Presence of a mechanical heart valve or any other medical condition requiring anticoagulation with a VKA
- Triple aPL positivity
- Pregnancy or breastfeeding
- Subject deprived of freedom, subject under a legal protective measure
- No affiliation to any health insurance system
- Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label, non-inferiority, randomized controlled trial with two parallel arms (experimental and control), following a PROBE (Prospective Randomized Open, Blinded Endpoint) design. The study evaluates whether anticoagulation cessation is non-inferior to anticoagulation maintenance regarding the risk of recurrent thrombosis after antiphospholipid antibodies (aPL) loss in patients with thrombotic antiphospholipid syndrome (APS). Currently, the cornerstone of APS treatment is long-term anticoagulation by vitamin K antagonists (VKAs), which expose patients to the risk of bleeding and have a negative impact on health-related quality of life due to the need for frequent International Normalized Ratio (INR) monitoring. No clinical trial in the existing literature has evaluated anticoagulant cessation after aPL loss. The primary endpoint is the first recurrent thrombotic event during follow-up.
The 2 groups in the trial
- Anticoagulation CessationTreatment being tested
Participants in this arm discontinue vitamin K antagonist (VKA) therapy at the randomisation visit. Anticoagulant treatment duration in this arm is 0 month. International Normalized Ratio (INR) testing is performed at baseline (M0) and then discontinued. Participants are followed according to the study visit schedule (M3, M6, then every 6 months up to M48), with clinical and biological assessments including antiphospholipid antibody (aPL) measurement, and are restarted on anticoagulant therapy only in case of a recurrent thrombotic event.
Treatment: Anticoagulant Therapy Discontinuation
- Anticoagulation MaintenanceExisting treatment, for comparison
Participants in this arm continue vitamin K antagonist (VKA) therapy (fluindione, warfarin, or acenocoumarol), dosed orally to obtain an International Normalized Ratio (INR) between 2 and 3, for a minimum of 24 months (up to 48 months depending on time of enrollment). INR is monitored at baseline (M0), at M3, at each subsequent protocol visit, in case of recurrent thrombotic event, and as clinically indicated. Participants are also followed with clinical and biological assessments including antiphospholipid antibody (aPL) measurement. Participants follow the same visit schedule as the experimental arm (M3, M6, then every 6 months up to M48)
Treatment: Vitamin K Antagonist - Drug
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomised Controlled Trial to Evaluate Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome
- Plain-language title
- Stopping blood thinners after antibodies disappear in thrombotic antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 15 October 2026